688166 博瑞医药
已收盘 02-13 15:00:01
资讯
新帖
简况
每周股票复盘：博瑞医药（688166）BGM0504中美临床进展及代谢管线布局
证券之星 · 02-15 01:39
每周股票复盘：博瑞医药（688166）BGM0504中美临床进展及代谢管线布局
博瑞医药(688166.SH)部分产品拟中选国家药品接续采购
智通财经 · 02-11
博瑞医药(688166.SH)部分产品拟中选国家药品接续采购
【私募调研记录】重阳投资调研博瑞医药
证券之星 · 02-10
【私募调研记录】重阳投资调研博瑞医药
每周股票复盘：博瑞医药（688166）2025年净利预降67.28%至78.17%
证券之星 · 02-01
每周股票复盘：博瑞医药（688166）2025年净利预降67.28%至78.17%
博瑞医药：2025年年度业绩预告
证券日报 · 01-30
博瑞医药：2025年年度业绩预告
每周股票复盘：博瑞医药（688166）决定不赎回博瑞转债
证券之星 · 01-11
每周股票复盘：博瑞医药（688166）决定不赎回博瑞转债
博瑞医药（688166）披露关于不提前赎回“博瑞转债”的公告，1月5日股价上涨7.48%
证券之星 · 01-05
博瑞医药（688166）披露关于不提前赎回“博瑞转债”的公告，1月5日股价上涨7.48%
博瑞医药（688166）披露2025年度持续督导现场检查报告，12月29日股价下跌0.96%
证券之星 · 2025-12-29
博瑞医药（688166）披露2025年度持续督导现场检查报告，12月29日股价下跌0.96%
每周股票复盘：博瑞医药（688166）博瑞转债2025年付息及可能触发赎回条款
证券之星 · 2025-12-28
每周股票复盘：博瑞医药（688166）博瑞转债2025年付息及可能触发赎回条款
博瑞医药（688166）发布关于“博瑞转债”预计满足赎回条件的提示性公告，12月25日股价上涨1.44%
证券之星 · 2025-12-25
博瑞医药（688166）发布关于“博瑞转债”预计满足赎回条件的提示性公告，12月25日股价上涨1.44%
12月15日博瑞医药跌6.09%，国泰上证科创板创新药ETF基金重仓该股
证券之星 · 2025-12-15
12月15日博瑞医药跌6.09%，国泰上证科创板创新药ETF基金重仓该股
每周股票复盘：博瑞医药（688166）将召开Q3业绩说明会
证券之星 · 2025-11-23
每周股票复盘：博瑞医药（688166）将召开Q3业绩说明会
每周股票复盘：博瑞医药（688166）拟5000万增资极客基因
证券之星 · 2025-11-16
每周股票复盘：博瑞医药（688166）拟5000万增资极客基因
博瑞医药（688166）披露关于召开2025年第二次临时股东会的通知，11月14日股价上涨0.85%
证券之星 · 2025-11-14
博瑞医药（688166）披露关于召开2025年第二次临时股东会的通知，11月14日股价上涨0.85%
博瑞医药最新公告：拟5000万元增资参股公司极客基因
证券之星 · 2025-11-14
博瑞医药最新公告：拟5000万元增资参股公司极客基因
博瑞医药递表港交所：估值偏高、业绩走弱、研发掉队、内控问题频发 资本市场是否买单？
新浪证券 · 2025-11-14
博瑞医药递表港交所：估值偏高、业绩走弱、研发掉队、内控问题频发 资本市场是否买单？
博瑞医药(688166.SH)：BGM1812注射液获得药物临床试验批准通知书
智通财经 · 2025-11-13
博瑞医药(688166.SH)：BGM1812注射液获得药物临床试验批准通知书
每周股票复盘：博瑞医药（688166）回购进展披露
证券之星 · 2025-11-09
每周股票复盘：博瑞医药（688166）回购进展披露
博瑞医药（688166）披露股份回购进展公告，11月03日股价上涨1.32%
证券之星 · 2025-11-03
博瑞医药（688166）披露股份回购进展公告，11月03日股价上涨1.32%
每周股票复盘：博瑞医药（688166）股东户数增104.44%，净利降71.64%
证券之星 · 2025-11-02
每周股票复盘：博瑞医药（688166）股东户数增104.44%，净利降71.64%
暂无数据
公司概况
公司名称：
博瑞生物医药(苏州)股份有限公司
所属行业：
医药制造业
上市日期：
2019-11-08
主营业务：
博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是抗病毒、抗真菌、免疫抑制、呼吸系统、抗肿瘤、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠。公司先后获得“国家知识产权示范企业”、“国家知识产权优势企业”、“2017年度中国专利优秀奖”、“第十一届中国药学会科学技术奖一等奖”等多项荣誉。
发行价格：
12.71
{"stockData":{"symbol":"688166","market":"SH","secType":"STK","nameCN":"博瑞医药","latestPrice":45.34,"timestamp":1770966001000,"preClose":46.01,"halted":0,"volume":4196749,"delay":0,"changeRate":-0.0146,"floatShares":423000000,"shares":423000000,"eps":0.1468,"marketStatus":"已收盘","change":-0.67,"latestTime":"02-13 15:00:01","open":46.3,"high":46.7,"low":45.27,"amount":193000000,"amplitude":0.0311,"askPrice":45.34,"askSize":59,"bidPrice":45.33,"bidSize":10,"shortable":0,"etf":0,"ttmEps":0.1468,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771896600000},"marketStatusCode":5,"adr":0,"adjPreClose":46.01,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770946200000,1770953400000],[1770958800000,1770966000000]],"highLimit":50.61,"lowLimit":41.41,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":423103851,"isCdr":false,"pbRate":8.04,"roa":"--","peRate":308.855586,"roe":"2.01%","epsLYR":0.45,"committee":-0.308585,"marketValue":19184000000,"turnoverRate":0.0099,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-02-24。","afterMarket":{"amount":0,"volume":0,"close":45.34,"buyVolume":700,"sellVolume":0,"time":1770968037558,"indexStatus":"已收盘 02-13 15:30:00","preClose":46.01},"floatMarketCap":19184000000},"requestUrl":"/m/hq/s/688166/tweets","defaultTab":"tweets","newsList":[{"id":"2611143237","title":"每周股票复盘：博瑞医药（688166）BGM0504中美临床进展及代谢管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2611143237","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611143237?lang=zh_cn&edition=full","pubTime":"2026-02-15 01:39","pubTimestamp":1771090749,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘，博瑞医药报收于45.34元，较上周的46.32元下跌2.12%。本周，博瑞医药2月10日盘中最高价报47.77元。本周关注点来自机构调研要点：BGM0504注射液国内III期临床已完成全部入组，处于给药和随访阶段。来自机构调研要点：MSTN环肽注射液与BGM0504联用可显著维持瘦体重。截至目前，BGM0504注射液减重适应症在美国的后续临床计划具有不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2610984945","title":"博瑞医药(688166.SH)部分产品拟中选国家药品接续采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2610984945","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610984945?lang=zh_cn&edition=full","pubTime":"2026-02-11 16:22","pubTimestamp":1770798164,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博瑞医药 发布公告，近日，公司全资子公司博瑞制药(苏州)有限公司参加了国家组织集采药品协议期满品种接续采购办公室组织的集采药品协议期满品种接续采购。公司本次拟中选的4个产品2025年前三季度合计销售额为8,884.75万元，占公司2025年前三季度营业收入比例为10.16%。在采购周期内，医疗机构将优先使用本次药品接续采购中选药品，并确保完成约定采购量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404148.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博瑞医药(688166.SH)部分产品拟中选国家药品接续采购","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2610667417","title":"【私募调研记录】重阳投资调研博瑞医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2610667417","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610667417?lang=zh_cn&edition=full","pubTime":"2026-02-10 08:12","pubTimestamp":1770682326,"startTime":"0","endTime":"0","summary":"根据市场公开信息及2月9日披露的机构调研信息，知名私募重阳投资近期对1家上市公司进行了调研，相关名单如下：1）博瑞医药 调研纪要：BGM0504注射液国内2型糖尿病和减重适应症III期临床已完成入组，美国减重适应症处于III期方案完善阶段，印尼已启动三期临床。在投资方法上，重阳投资注重研究驱动的投资，强调严谨科学的投资流程在投资中的重要性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026021000005941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2608077338","title":"每周股票复盘：博瑞医药（688166）2025年净利预降67.28%至78.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608077338","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608077338?lang=zh_cn&edition=full","pubTime":"2026-02-01 02:19","pubTimestamp":1769883550,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，博瑞医药报收于46.79元，较上周的50.81元下跌7.91%。本周，博瑞医药1月26日盘中最高价报51.35元。公司公告汇总博瑞医药预计2025年年度实现归属于母公司所有者的净利润4,130万元到6,190万元，同比减少67.28%到78.17%；扣除非经常性损益的净利润430万元到2,490万元，同比减少86.21%到97.62%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000626.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2607017823","title":"博瑞医药：2025年年度业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2607017823","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607017823?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:06","pubTimestamp":1769771160,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月30日，博瑞医药（维权）发布2025年年度业绩预告称，公司预计2025年年度归属于母公司所有者的净利润4，130万元到6，190万元，与上年同期（法定披露数据）相比将同比减少67.28%到78.17%。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-30/doc-inhkauvf3557303.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-30/doc-inhkauvf3557303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2602535803","title":"每周股票复盘：博瑞医药（688166）决定不赎回博瑞转债","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535803","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535803?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:24","pubTimestamp":1768069453,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，博瑞医药报收于54.6元，较上周的49.06元上涨11.29%。本周关注点公司公告汇总：博瑞医药决定不行使“博瑞转债”提前赎回权，且未来三个月内若再触发亦不行使。公司公告汇总博瑞医药发行的“博瑞转债”自2025年12月12日至2026年1月5日已有15个交易日收盘价不低于当期转股价格的130%，已触发有条件赎回条款。截至2025年12月31日，累计已有22,228,000元博瑞转债转换为股票，累计转股638,885股，占转股前总股本的0.1558%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2601040882","title":"博瑞医药（688166）披露关于不提前赎回“博瑞转债”的公告，1月5日股价上涨7.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601040882","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601040882?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:15","pubTimestamp":1767622511,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，博瑞医药报收于52.73元，较前一交易日上涨7.48%，最新总市值为223.1亿元。公司近日发布公告称，博瑞生物医药（苏州）股份有限公司股票自2025年12月12日至2026年1月5日满足连续30个交易日中至少15个交易日收盘价不低于当期转股价格的130%，已触发“博瑞转债”有条件赎回条款。相关主体在赎回条件满足前六个月内未减持可转债。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500039936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2595926735","title":"博瑞医药（688166）披露2025年度持续督导现场检查报告，12月29日股价下跌0.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595926735","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595926735?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:20","pubTimestamp":1767018035,"startTime":"0","endTime":"0","summary":"截至2025年12月29日收盘，博瑞医药报收于49.73元，较前一交易日下跌0.96%，最新总市值为210.41亿元。该股当日开盘50.26元，最高50.26元，最低49.31元，成交额达2.47亿元，换手率为1.17%。近日，国联民生证券承销保荐有限公司发布了关于博瑞生物医药（苏州）股份有限公司2025年度持续督导工作现场检查报告。公告显示，保荐机构对公司治理和内部控制、信息披露、独立性、募集资金使用、关联交易、对外担保、重大对外投资及经营状况等方面进行了现场检查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900037801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2594241072","title":"每周股票复盘：博瑞医药（688166）博瑞转债2025年付息及可能触发赎回条款","url":"https://stock-news.laohu8.com/highlight/detail?id=2594241072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594241072?lang=zh_cn&edition=full","pubTime":"2025-12-28 02:15","pubTimestamp":1766859313,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，博瑞医药报收于50.21元，较上周的48.6元上涨3.31%。本周，博瑞医药12月26日盘中最高价报50.97元。关于“博瑞转债”预计满足赎回条件的提示性公告博瑞生物医药（苏州）股份有限公司于2022年1月4日发行465万张可转换公司债券，发行总额46,500万元，债券简称“博瑞转债”，代码118004，转股期为2022年7月11日至2028年1月3日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2594237670","title":"博瑞医药（688166）发布关于“博瑞转债”预计满足赎回条件的提示性公告，12月25日股价上涨1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594237670","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594237670?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:21","pubTimestamp":1766672477,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，博瑞医药报收于50.63元，较前一交易日上涨1.44%，最新总市值为214.22亿元。近日，博瑞生物医药（苏州）股份有限公司发布关于“博瑞转债”预计满足赎回条件的提示性公告。公告显示，公司于2022年1月4日发行465万张可转换公司债券，发行总额46,500万元，债券简称“博瑞转债”，代码118004，转股期为2022年7月11日至2028年1月3日。截至2025年12月25日，公司股票已有十个交易日收盘价不低于当期转股价格的130%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500036048.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2591615355","title":"12月15日博瑞医药跌6.09%，国泰上证科创板创新药ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591615355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591615355?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:34","pubTimestamp":1765784071,"startTime":"0","endTime":"0","summary":"证券之星消息，12月15日博瑞医药跌6.09%，收盘报49.94元，换手率3.52%，成交量14.9万手，成交额7.56亿元。重仓博瑞医药的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共11家，其中持有数量最多的公募基金为国泰基金的国泰上证科创板创新药ETF。国泰上证科创板创新药ETF目前规模为4.26亿元，最新净值0.9383，较上一交易日上涨0.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500012958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159982","510300","000905.SH","BK0239","688166","399001","000001.SH","515890","399006","510880","512880","512510","159967","399300","000300.SH","000688.SH","515120"],"gpt_icon":0},{"id":"2585510849","title":"每周股票复盘：博瑞医药（688166）将召开Q3业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2585510849","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585510849?lang=zh_cn&edition=full","pubTime":"2025-11-23 01:39","pubTimestamp":1763833148,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，博瑞医药报收于48.87元，较上周的54.85元下跌10.9%。本周关注点公司公告汇总：博瑞医药将召开2025年第三季度业绩说明会。公司公告汇总博瑞生物医药（苏州）股份有限公司将于2025年12月2日13:00-14:00通过上证路演中心网络文字互动方式召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果及财务状况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2583656944","title":"每周股票复盘：博瑞医药（688166）拟5000万增资极客基因","url":"https://stock-news.laohu8.com/highlight/detail?id=2583656944","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583656944?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:17","pubTimestamp":1763227028,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，博瑞医药报收于54.85元，较上周的53.22元上涨3.06%。本周，博瑞医药11月14日盘中最高价报56.8元。公司公告汇总：博瑞医药拟出资5000万元对苏州极客基因科技有限公司进行增资。公司拟出资5,000万元对苏州极客基因科技有限公司增资，认购其新增注册资本43.7100万元，持股比例由4.0816%增至12.8015%。本次对极客基因的增资构成关联交易，因公司董事长袁建栋担任极客基因董事，且为其关联自然人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2583504321","title":"博瑞医药（688166）披露关于召开2025年第二次临时股东会的通知，11月14日股价上涨0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583504321","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583504321?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:12","pubTimestamp":1763129548,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，博瑞医药报收于54.85元，较前一交易日上涨0.85%，最新总市值为232.07亿元。该股当日开盘55.54元，最高56.8元，最低54.22元，成交额达8.15亿元，换手率为3.48%。公司近日发布公告称，将于2025年12月1日召开2025年第二次临时股东会，会议采取现场与网络投票相结合方式，网络投票通过上交所系统进行。股权登记日为2025年11月25日，登记时间2025年11月26日。现场会议地点为苏州工业园区启月街299号独墅湖世尊酒店M9会议室。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2583613574","title":"博瑞医药最新公告：拟5000万元增资参股公司极客基因","url":"https://stock-news.laohu8.com/highlight/detail?id=2583613574","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583613574?lang=zh_cn&edition=full","pubTime":"2025-11-14 18:00","pubTimestamp":1763114400,"startTime":"0","endTime":"0","summary":"博瑞医药(688166.SH)公告称，公司拟对苏州极客基因科技有限公司增资5000万元，认缴极客基因新增注册资本43.7100万元，增资后持有极客基因12.8015%股权。公司董事长袁建栋、苏州鸿博创业投资合伙企业（有限合伙）、苏州鸿博二期投资合伙企业（有限合伙）为本轮增资前现有股东，且袁建栋担任极客基因董事。本次交易构成关联交易，未构成重大资产重组。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400029448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2583529354","title":"博瑞医药递表港交所：估值偏高、业绩走弱、研发掉队、内控问题频发 资本市场是否买单？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583529354","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583529354?lang=zh_cn&edition=full","pubTime":"2025-11-14 13:53","pubTimestamp":1763099580,"startTime":"0","endTime":"0","summary":" 近日，博瑞生物医药（苏州）股份有限公司正式向港交所递交招股书，拟于主板挂牌上市。博瑞医药（维权）此次谋求A+H双平台上市，表面理由是加快国际化战略及海外业务布局，但其背后，却是业绩骤降、现金流紧绷、定增告吹后的融资困局。在A股定增终止的背景下，博瑞医药赴港上市被视为缓解资金压力的重要途径，但在估值偏高、业绩走弱、研发掉队、内控问题频发的背景下，资本市场是否会买单，还是未知数。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-11-14/doc-infxkanu9178753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688166","BK0239","HEXmain"],"gpt_icon":0},{"id":"2583548515","title":"博瑞医药(688166.SH)：BGM1812注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2583548515","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583548515?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:13","pubTimestamp":1763021585,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博瑞医药 发布公告，公司全资子公司博瑞制药(苏州)有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意博瑞制药BGM1812注射液开展超重或肥胖的临床试验。BGM1812注射液是公司优化设计的新型长效Amylin类似物，具有良好的分子活性和药学稳定性。截至公告披露日，BGM1812注射液减重适应症在美国已获得FDA的药品临床试验批准，首例临床入组已完成。截至公告披露日，全球尚无同类靶点制剂减重适应症获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"博瑞医药(688166.SH)：BGM1812注射液获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2582360866","title":"每周股票复盘：博瑞医药（688166）回购进展披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2582360866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582360866?lang=zh_cn&edition=full","pubTime":"2025-11-09 01:21","pubTimestamp":1762622469,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，博瑞医药报收于53.22元，较上周的57.4元下跌7.28%。本周，博瑞医药11月3日盘中最高价报58.74元。博瑞医药当前最新总市值225.18亿元，在化学制药板块市值排名23/151，在两市A股市值排名867/5166。本周关注点公司公告汇总：截至2025年10月31日，博瑞医药累计回购股份55,880股，支付资金总额2,993,933.37元。回购进展符合规定，后续将履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0},{"id":"2580921165","title":"博瑞医药（688166）披露股份回购进展公告，11月03日股价上涨1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580921165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580921165?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:22","pubTimestamp":1762179773,"startTime":"0","endTime":"0","summary":"截至2025年11月3日收盘，博瑞医药报收于58.16元，较前一交易日上涨1.32%，最新总市值为246.08亿元。该股当日开盘58.74元，最高58.74元，最低56.66元，成交额达8.32亿元，换手率为3.41%。公司近日发布关于股份回购进展的公告。公告显示，公司于2025年9月26日召开董事会审议通过回购股份方案，拟使用自有资金以集中竞价交易方式回购股份，用于员工持股计划或股权激励。上述回购进展符合相关规定及公司回购方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300035904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"gpt_icon":0},{"id":"2580478701","title":"每周股票复盘：博瑞医药（688166）股东户数增104.44%，净利降71.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580478701","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580478701?lang=zh_cn&edition=full","pubTime":"2025-11-02 01:45","pubTimestamp":1762019114,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，博瑞医药报收于57.4元，较上周的53.39元上涨7.51%。本周，博瑞医药10月31日盘中最高价报59.44元。业绩披露要点博瑞医药2025年三季报显示，前三季度主营收入8.74亿元，同比下降10.5%；归母净利润5032.0万元，同比下降71.64%；扣非净利润4617.23万元，同比下降73.41%。公司公告汇总2025年第三季度，公司产品销售收入78,465.38万元，同比减少10.59%；原料药收入67,007.26万元，同比减少8.97%；制剂收入11,458.12万元，同比减少19.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771297256906,"stockEarnings":[{"period":"1week","weight":-0.0212},{"period":"1month","weight":-0.1442},{"period":"3month","weight":-0.1734},{"period":"6month","weight":-0.6044},{"period":"1year","weight":0.5616},{"period":"ytd","weight":-0.0758}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博瑞生物医药(苏州)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"19561人(较上一季度增加104.44%)","perCapita":"21629股","listingDate":"2019-11-08","address":"江苏省苏州市吴中区工业园区星湖街218号纳米科技园C25栋","registeredCapital":"42310万元","survey":" 博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是抗病毒、抗真菌、免疫抑制、呼吸系统、抗肿瘤、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠。公司先后获得“国家知识产权示范企业”、“国家知识产权优势企业”、“2017年度中国专利优秀奖”、“第十一届中国药学会科学技术奖一等奖”等多项荣誉。","listedPrice":12.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博瑞医药,688166,博瑞医药股票,博瑞医药股票老虎,博瑞医药股票老虎国际,博瑞医药行情,博瑞医药股票行情,博瑞医药股价,博瑞医药股市,博瑞医药股票价格,博瑞医药股票交易,博瑞医药股票购买,博瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}